NextCell Pharma AB (NXTCL.ST) Research

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.

Market snapshot

Symbol
NXTCL.ST
Price
$1.05
Day change
-1.13%
Market cap
$117.4M
P/E ratio
-2.45x
52-week range
0.63-1.784
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Active Biotech AB (publ) (ACTI.ST)
  • Biosergen AB (BIOSGN.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
  • Iconovo AB (publ) (ICO.ST)
  • Immunovia AB (publ) (IMMNOV.ST)
  • Nanologica AB (publ) (NICA.ST)
  • Pila Pharma AB (publ) (PILA.ST)

Open NextCell Pharma AB (NXTCL.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.